Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease

References

• Pearson CM. Polymyositis and dermatomyositis. In: McCarty DJ, editor. Arthritis and allied conditions: A textbook of rheumatology. 9th ed. Philadelphia (PA): Lea and Febiger; 1979. p. 742.
   Google Scholar
• Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–636.
   PubMed Web of Science ®Google Scholar
• Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986;80(2):329–332.
   Web of Science ®Google Scholar
• High WA, Cohen JB, Murphy BA, et al. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. J Am Acad Dermatol. 2003;49(2):295–298.
   PubMed Web of Science ®Google Scholar
• Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44(10):1282–1286.
   PubMed Web of Science ®Google Scholar
• Neuhaus IM, Connolly MK. An unusual presentation of amyopathic dermatomyositis associated with fatal interstitial lung disease. Arch Dermatol. 2006;142(1):113–114.
   Google Scholar
• Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28(5):1005–1012.
   Web of Science ®Google Scholar
• Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26(10):1647–1654.
   PubMed Web of Science ®Google Scholar
• Ideura G, Hanaoka M, Koizumi T, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med. 2007;101(7):1406–1411.
   Web of Science ®Google Scholar
• Miyazaki E, Ando M, Muramatsu T, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007;26(3):436–439.
   Web of Science ®Google Scholar
• Kakugawa T, Mukae H, Saito M, et al. Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med. 2008;47(8):785–790.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–1576.
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, et al. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2012;22(4):625–629.
   PubMed Web of Science ®Google Scholar
• Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–2200.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–440.
   PubMed Web of Science ®Google Scholar
• Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488–498.
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496–502.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies. Clin Rheumatol. 2017;36(1):239–240.
   Web of Science ®Google Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–293.
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114–2119.
   PubMed Web of Science ®Google Scholar
• So H, Wong VTL, Lao VWN, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018;37(7):1983–1989.
   PubMed Web of Science ®Google Scholar
• Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017;177(5):1442–1446.
   Web of Science ®Google Scholar
• Teruya A, Kawamura K, Ichikado K, et al. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest. 2013;144(6):1934–1936.
   PubMed Web of Science ®Google Scholar
• Endo Y, Koga T, Suzuki T, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report. Medicine (Baltimore). 2018;97(15):e0436.
   Web of Science ®Google Scholar
• Bozkirli DE, Kozanoglu I, Bozkirli E, et al. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis. J Clin Apher. 2013;28(6):422–425.
   PubMed Web of Science ®Google Scholar
• Omotoso BA, Ogden MI, Balogun RA. Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease. J Clin Apher. 2015;30(6):375–379.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Selva-O’allaghan A, Ramos-Terrades N, et al. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM. 2016;109(1):49–50.
   Web of Science ®Google Scholar
• Yagishita M, Kondo Y, Terasaki T, et al. Clinically amyopathic dermatomyositis with interstitial pneumonia that was successfully treated with plasma exchange. Intern Med. 2018;57(13):1935–1938.
   Web of Science ®Google Scholar
• Fujita Y, Fukui S, Suzuki T, et al. Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis. Intern Med. 2018;57(23):3473–3478.
   Web of Science ®Google Scholar
• Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020;keaa123. 2020 Apr 10;keaa123. doi:10.1093/rheumatology/keaa123. Online ahead of print.
   Google Scholar
• Gono T, Kuwana M. Inflammatory myopathies: choosing the right biomarkers to predict ILD in myositis. Nat Rev Rheumatol. 2016;12(9):504–506.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiationassociated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713–1719.
   PubMed Web of Science ®Google Scholar
• Xu Y, Yang CS, Li YJ, et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol. 2016;35(1):113–116.
   Web of Science ®Google Scholar
• Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis- associated interstitial lung disease. Respir Med. 2016;121:91–99.
   PubMed Web of Science ®Google Scholar
• Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278–1284.
   PubMed Web of Science ®Google Scholar
• Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med. 2013;107(5):745–752.
   Web of Science ®Google Scholar
• Fujiki Y, Kotani T, Isoda K, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018;28(1):133–140.
   PubMed Web of Science ®Google Scholar
• Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018;57(7):1212–1221.
   PubMed Web of Science ®Google Scholar
• Gono T, Masui K, Kawaguchi Y, et al. Predictive modeling of mortality in polymyositis/dermatomyositis patients with interstitial lung disease based on combination of serum myositis-specific autoantibodies and conventional biomarkers. ACR Meeting. San Diego (CA): ACR; 2017.
   Google Scholar
• Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395–402.
   PubMed Web of Science ®Google Scholar